BNP Paribas Financial Markets Purchases 29,936 Shares of argenx SE (NASDAQ:ARGX)

BNP Paribas Financial Markets grew its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 36.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 111,048 shares of the company's stock after buying an additional 29,936 shares during the period. BNP Paribas Financial Markets owned 0.19% of argenx worth $42,246,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Principal Securities Inc. purchased a new stake in argenx in the fourth quarter valued at approximately $99,000. TimesSquare Capital Management LLC raised its stake in argenx by 10.8% in the fourth quarter. TimesSquare Capital Management LLC now owns 112,705 shares of the company's stock valued at $42,876,000 after purchasing an additional 10,955 shares in the last quarter. Maryland State Retirement & Pension System purchased a new stake in argenx in the fourth quarter valued at approximately $733,000. Benjamin F. Edwards & Company Inc. purchased a new stake in argenx in the fourth quarter valued at approximately $60,000. Finally, First Trust Direct Indexing L.P. raised its stake in argenx by 41.8% in the fourth quarter. First Trust Direct Indexing L.P. now owns 1,659 shares of the company's stock valued at $631,000 after purchasing an additional 489 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Price Performance

NASDAQ:ARGX traded down $15.15 during trading hours on Monday, hitting $359.48. The company had a trading volume of 343,985 shares, compared to its average volume of 311,999. The company has a market capitalization of $21.36 billion, a PE ratio of -63.51 and a beta of 0.67. The stock has a 50-day moving average price of $382.64 and a 200 day moving average price of $408.67. argenx SE has a 52 week low of $327.73 and a 52 week high of $550.76.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.33). The company had revenue of $412.51 million during the quarter, compared to the consensus estimate of $404.03 million. argenx had a negative net margin of 22.58% and a negative return on equity of 14.14%. During the same quarter last year, the firm earned ($0.52) EPS. Analysts anticipate that argenx SE will post -2.18 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Wolfe Research started coverage on shares of argenx in a research note on Thursday, February 15th. They issued a "peer perform" rating on the stock. Wells Fargo & Company increased their price target on shares of argenx from $472.00 to $478.00 and gave the company an "overweight" rating in a research report on Tuesday, February 20th. JMP Securities reduced their price target on shares of argenx from $471.00 to $468.00 and set a "market outperform" rating on the stock in a research report on Friday. Wedbush reiterated an "outperform" rating and set a $521.00 price target on shares of argenx in a research report on Thursday, April 18th. Finally, Scotiabank increased their price target on shares of argenx from $402.00 to $408.00 and gave the company a "sector perform" rating in a research report on Tuesday, March 26th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, argenx currently has an average rating of "Moderate Buy" and an average price target of $524.68.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.